Biosimilars are, as the name would suggest, highly similar and are a more affordable alternative to biologics that is poised to influence the current dynamics of the immunology market. ...Read More
The new drug, Imraldi, marks the third European Commission approval for “biosimilar” versions from the joint venture, Samsung Bioepis, of drugs in a class known as TNF inhibitors....Read More
Sandoz, a Novartis division, recently announced that The Canadian Drug Expert Committee (CDEC) as part of the Common Drug Review (CDR) process has issued a positive drug reimbursement recommendation f...Read More